David Habiger Buys 1,042 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger bought 1,042 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.07 per share, with a total value of $50,088.94. Following the transaction, the director directly owned 14,920 shares in the company, valued at approximately $717,204.40. This trade represents a 7.51% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Boston Scientific Trading Up 3.0%

NYSE:BSX opened at $49.19 on Friday. The firm’s fifty day moving average is $45.73 and its 200-day moving average is $60.81. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.22 and a current ratio of 1.24. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The firm has a market cap of $71.28 billion, a P/E ratio of 19.91, a P/E/G ratio of 1.04 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplicity Wealth LLC bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $481,000. Trivium Point Advisory LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at $1,476,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Boston Scientific in the 2nd quarter valued at $6,736,000. HBK Sorce Advisory LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $402,000. Finally, Gould Asset Management LLC CA bought a new stake in Boston Scientific during the 2nd quarter valued at $445,000. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on BSX. Leerink Partners set a $60.00 target price on Boston Scientific in a research note on Thursday, July 30th. Bank of America cut their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. TD Cowen reduced their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. UBS Group lowered their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Citigroup dropped their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.